These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 24399611)
1. Molecular and genetic diversity in the metastatic process of melanoma. Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611 [TBL] [Abstract][Full Text] [Related]
2. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation. Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541 [TBL] [Abstract][Full Text] [Related]
3. Lack of distinct molecular profile of Primary Dermal Melanoma. Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880 [TBL] [Abstract][Full Text] [Related]
4. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967 [TBL] [Abstract][Full Text] [Related]
5. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433 [TBL] [Abstract][Full Text] [Related]
6. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases. Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543 [TBL] [Abstract][Full Text] [Related]
7. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker. Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Yaman B; Akalin T; Kandiloğlu G Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015 [TBL] [Abstract][Full Text] [Related]
9. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240 [TBL] [Abstract][Full Text] [Related]
10. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760 [TBL] [Abstract][Full Text] [Related]
11. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188 [TBL] [Abstract][Full Text] [Related]
13. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Turajlic S; Furney SJ; Stamp G; Rana S; Ricken G; Oduko Y; Saturno G; Springer C; Hayes A; Gore M; Larkin J; Marais R Ann Oncol; 2014 May; 25(5):959-67. PubMed ID: 24504448 [TBL] [Abstract][Full Text] [Related]
14. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]